4-phenylphenylpyruvic acid | 91853-46-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-phenylphenylpyruvic acid
• 英文别名: 3-([1,1'-biphenyl]-4-yl)-2-oxopropanoic acid；biphenyl-4-yl-pyruvic acid；Biphenyl-4-yl-brenztraubensaeure；4-biphenylyl-pyruvic acid；4-biphenyl-pyruvic acid；2-Oxo-3-(4-phenylphenyl)propanoic acid
• CAS: 91853-46-2
• 化学式: C₁₅H₁₂O₃
• mdl: MFCD09737957
• 分子量: 240.258
• InChiKey: YLSFJNHIOYAOHZ-UHFFFAOYSA-N

物化性质

• 熔点：
  205 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  421.8±34.0 °C(Predicted)
• 密度：
  1.227±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.066
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-phenylphenylpyruvic acid 在 dipotassium hydrogenphosphate 、 氯化亚砜 、 磷酸吡哆醛 、 异丙基氨盐酸盐 、 三乙胺 作用下， 以 水 、 甲苯 为溶剂， 反应 30.58h， 生成 N-叔丁基氧基羰基-氨基-4,4-联苯-R-丙氨酸甲酯
  参考文献：
  名称：

  [EN] NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES
  [FR] NOUVEAU PROCÉDÉ POUR DES INTERMÉDIAIRES DE SACUBITRIL PRÉCOCES

  摘要：

  这项发明涉及一种新的对映选择性工艺，用于生产用于制造NEP抑制剂或其前药的有用中间体，特别是包含γ-氨基-δ-联苯基-α-甲基烷酸或酸酯骨架的NEP抑制剂。

  公开号：

  WO2018116203A1
• 作为产物：
  描述：

  4-氯甲基联苯 在 sodium hydroxide 、 sodium acetate 、 乙酸酐 、 溶剂黄146 作用下， 生成 4-phenylphenylpyruvic acid
  参考文献：
  名称：

  Further Research on Biphenyl, Stilbene and Diphenylethane Derivatives—Potential Anticholesterinemic, Antirheumatic Drugs. VII

  摘要：

  DOI：

  10.1021/ja01570a057

文献信息

• Phosphono/biaryl substituted dipetide derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05294632A1

  公开（公告）日：1994-03-15

  The invention relates to the N-phosphonomethyl-biaryl substituted dipeptide derivatives of formula I ##STR1## and tetrazole derivatives of the formula Ia ##STR2## wherein A represents a direct bond, lower alkylene, phenylene or cyclohexylene; m represents 1 or zero, provided that m represents 1 when A is a direct bond; R.sub.2 represents hydrogen, hydroxy, lower alkyl, aryl-lower alkyl, C.sub.5 -C.sub.7 -cycloalkyl-lower alkyl, amino-lower alkyl, hydroxy-lower alkyl, lower alkylthio-lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkylthio-lower alkyl or aryl-lower alkoxy-lower alkyl; biaryl represents phenyl substituted by carbocyclic or heterocyclic aryl; and pharmaceutically acceptable mono-, di- or tri-ester derivatives thereof in which one, two or three of the acidic hydroxy groups of the carboxyl and/or phosphono functional groups are esterified in form of a mono-, di- or tri-pharmaceutically acceptable ester; and pharmaceutically acceptable amide derivatives thereof wherein the carboxyl group is derivatized in form of a pharmaceutically acceptable amide; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for the preparation of said compounds and for the preparation of intermediates; and methods of treating disorders in mammals which are responsive to the inhibition of neutral endopeptidases by administration of said compounds to mammals in need of such treatment.

  该发明涉及公式I的N-磷酸甲基-联苯基取代二肽衍生物以及公式Ia的四唑衍生物，其中A代表直接键，较低的烷基，苯基或环己烷基；m代表1或零，但当A为直接键时，m代表1；R.sub.2代表氢，羟基，较低的烷基，芳基-较低的烷基，C.sub.5-C.sub.7-环烷基-较低的烷基，氨基-较低的烷基，羟基-较低的烷基，较低的硫代烷基-较低的烷基，较低的氧代烷基-较低的烷基，芳基-较低的烷基硫代烷基或芳基-较低的烷基氧代烷基；联苯基代表被碳环或杂环芳基取代的苯基；以及其药学上可接受的单酯、二酯或三酯衍生物，其中羧基和/或磷酸基的酸性羟基中的一个、两个或三个以单酯、二酯或三酯药学上可接受的酯的形式酯化；以及其药学上可接受的酰胺衍生物，其中羧基以药学上可接受的酰胺形式衍生化；以及其药学上可接受的盐；包括所述化合物的药物组合物；制备所述化合物和中间体的方法；以及通过向需要此类治疗的哺乳动物施用所述化合物来抑制中性内肽酶以治疗哺乳动物疾病的方法。
• Phosphono/biaryl substituted dipeptide derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05155100A1

  公开（公告）日：1992-10-13

  The invention relates to the N-phosphonomethyl-biaryl substituted dipeptide derivatives of formula I ##STR1## wherein A represents a direct bond, lower alkylene, phenylene or cyclohexylene; m represents 1 or zero, provided that m represents 1 when A is a direct bond; R.sub.2 represents hydrogen, hydroxy, lower alkyl, aryl-lower alkyl, C.sub.5 -C.sub.7 -cycloalkyl-lower alkyl, amino-lower alkyl, hydroxyl-lower alkyl, lower alkylthio-lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkylthio-lower alkyl or aryl-lower alkoxy-lower alkyl; biaryl represents phenyl substituted by carbocyclic or heterocyclic aryl; and pharmaceutically acceptable mono-, di- or tri-ester derivatives thereof in which one, two or three of the acidic hydroxy groups of the carboxyl and phosphono functional groups are esterified in form of a mono-, di- or tri- pharmaceutically acceptable ester; and pharmaceutically acceptable amide derivatives thereof wherein the carboxyl group is derivatized in form of a pharmaceutically acceptable amide; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for the preparation of said compounds and for the preparation of intermediates; and methods of treating disorders in mammals which are responsive to the inhibition of neutral endopeptidases by administration of said compounds to mammals in need of such treatment.

  该发明涉及公式I的N-磷酸甲基-联苯基取代二肽衍生物，其中A代表直链键，较低的烷基，苯基或环己烷基；m代表1或零，前提是当A为直链键时m代表1；R.sub.2代表氢，羟基，较低的烷基，芳基-较低的烷基，C.sub.5-C.sub.7-环烷基-较低的烷基，氨基-较低的烷基，羟基-较低的烷基，较低的硫代烷基-较低的烷基，较低的氧代烷基-较低的烷基，芳基-较低的烷基硫代烷基或芳基-较低的烷基氧代烷基；联苯基代表被碳环或杂环芳基取代的苯基；以及其药学上可接受的单酯，二酯或三酯衍生物，其中羧基和磷酸甲酯官能团的三个酸性羟基中的一个，两个或三个以单酯，二酯或三酯药学上可接受的酯的形式酯化；以及其药学上可接受的酰胺衍生物，其中羧基以药学上可接受的酰胺形式衍生化；以及其药学上可接受的盐；包括所述化合物的药物组合物；制备所述化合物和中间体的方法；以及通过向需要此类治疗的哺乳动物施用所述化合物来抑制中性内肽酶以治疗哺乳动物疾病的方法。
• Synthesis and aldose reductase-inhibitory activities of structural analogues of WF-3681, a novel aldose reductase inhibitor.
  作者：TAKAYUKI NAMIKI、YUKIHISA BABA、YASUTAKA SUZUKI、MOTOAKI NISHIKAWA、KOZO SAWADA、YOSHIKUNI ITOH、TERUO OKU、YOSHIHIKO KITAURA、MASASHI HASHIMOTO

  DOI：10.1248/cpb.36.1404

  日期：——

  Various analogues of WF-3681 (1a), a novel aldose reductase inhibitor, were synthesized and examined for aldose reductase-inhibitory activity. It was found that the carboxylic acid function is necessary and the side-chain length is important for the activity. Furthermore, the lipophilicities of the benzene ring and the enol ether group are significant for increasing the activity.

  合成了多种WF-3681（1a）的类似物，这是一种新型的醛糖还原酶抑制剂，并对其醛糖还原酶抑制活性进行了研究。结果发现，羧酸基团是必要的，侧链长度对活性也很重要。此外，苯环和烯醇醚基团的脂溶性对提高活性具有重要意义。
• 一种沙库巴曲关键中间体的制备方法
  申请人：常州亚邦制药有限公司

  公开号：CN108675943A

  公开（公告）日：2018-10-19

  本发明公开了一种沙库巴曲关键中间体N‑[(1R)‑2‑[1,1′‑联苯]‑4‑基‑1‑(羟基甲基)乙基]氨基甲酸叔丁酯的合成制备方法。该制备方法以4‑联苯甲醛与乙内酰脲为起始原料，经过缩合和水解“一锅法”反应、酯化反应、不对称转氨化反应、Boc保护和还原反应来合成制备目标产品。该制备方法具有反应原料易得、路线短、反应立体选择性高、条件温和、工艺操作简便等特点，适合工业化生产。
• Substituted dipeptides as inhibitors of enkephalinases
  申请人：Schering Corporation

  公开号：US04906615A1

  公开（公告）日：1990-03-06

  A method for inhibiting the action of enkephalinases in a mannal to thereby elicit an analgesic effect in said mammal is described. Novel compounds and compositions useful for accomplishing the method of the invention are also described.

  本文描述了一种抑制哌啶肽酶在哺乳动物体内的作用以引发镇痛效应的方法。还描述了用于完成本发明方法的新型化合物和组合物。